Search results
Results from the WOW.Com Content Network
The transaction, which amounts to $330 per share in cash, offers a premium of 53% over Karuna's stock on Thursday. Bristol Myers Squibb acquires Karuna Therapeutics for $14 billion, boosting ...
Karuna Therapeutics' Schizophrenia Drug Could Be a Blockbuster ... its stock is down about 11%. ... with a high target price of $200 and an average of $175.
Under the terms of the deal, Bristol would pay $330 a share in cash for Karuna, which represents a 53.4% premium to its last closing price. Karuna's shares rose to $316.80 in early trading ...
The acquisition included Karuna's lead asset, KarXT, an investigational muscarinic antipsychotic combination of Xanomeline and Trospium. [86] In November 2023, the FDA accepted Karuna Therapeutics' NDA for KarXT, for the treatment of schizophrenia in adults. [87] The acquisition of Karuna Therapeutics was completed in March 2024. [88]
Karuna Therapeutics (KRTX) reports dismal third-quarter 2022 results. The company misses estimates for earnings and sales.
With a PANSS improvement of 7.5, NBI-111758 lagged behind xanomeline/trospium (KarXT) (Karuna Therapeutics) with 8.4 and emraclidine (Cerevel Therapeutics) with 12.7, both of which were in clinical trials at the same time. Moreover, the lack of dose-dependency led to disappointment in the stock market. [18]
Previous logo. Companies which PureTech Health founded include Karuna Pharmaceuticals, [4] Gelesis, which has received FDA approval as a treatment for weight management, [5] Akili Interactive Labs, which is developing a digital therapeutic platform for cognitive disorders, [6] Vedanta Biosciences, which is developing drugs to treat autoimmune and inflammatory diseases, [7] and Follica which is ...
Facebook, a stock hedge funds have loved dearly, lost nearly 40% of its value at one point in 2018. Although hedge funds are not perfect, their consensus picks do deliver solid returns, however ...